



Internationally indexed journal

Indexed in Chemical Abstract Services (USA), Index copernicus, Ulrichs Directory of Periodicals, Google scholar, CABI ,DOAJ , PSOAR, EBSCO , Open J gate , Proquest , SCOPUS , EMBASE ,etc.



Rapid and Easy Publishing

The "International Journal of Pharma and Bio Sciences" (IJPBS) is an international journal in English published quarterly. The aim of IJPBS is to publish peer reviewed research and review articles rapidly without delay in the developing field of pharmaceutical and biological sciences



Pharmaceutical Sciences

- Pharmaceutics
- Novel drug delivery system
- Nanotechnology
- Pharmacology
- Pharmacognosy
- Analytical chemistry
- Pharmacy practice
- Pharmacogenomics



Biological Sciences

- Polymer sciences
- Biomaterial sciences
- Medicinal chemistry
- Natural chemistry
- Biotechnology
- Pharmacoinformatics
- Biopharmaceutics
- Biochemistry
- Biotechnology
- Bioinformatics
- Cell biology
- Microbiology
- Molecular biology
- Neurobiology
- Cytology
- Pathology
- Immunobiology

**Indexed in Elsevier Bibliographic Database
(Scopus and EMBASE)**

SCImago Journal Rank 0.288

Impact factor 2.958*

Chemical Abstracts
Service (www.cas.org)



A division of the American Chemical Society

CODEN IJPBJ2



Elsevier Bibliographic databases (Scopus & Embase)

SNIP value – 0.77

SJR - 0.288

IPP - 0.479

SNIP – Source normalised impact per paper

SJR – SCImago Journal rank

IPP – Impact per publication

Source – www.journalmetrics.com

(Powered by scopus (ELSEVIER))



LUND
UNIVERSITY



JACKSONVILLE STATE UNIVERSITY

Jacksonville State University
Houston Cole Library
USA (Alabama)



UNIVERSITY OF
OXFORD

Oxford, United Kingdom

INDEX COPERNICUS
INTERNATIONAL

*And indexed/catalogued in
many more university*



*Instruction to Authors visit www.ijpbs.net

For any Queries, visit "contact" of www.ijpbs.net

**ASSOCIATION OF PROSTATE DISORDERS WITH RENAL DYSFUNCTION:
ROLE OF BIOCHEMICAL MARKERS****RESHMA K , Dr.SUDHA K* AND MAMATHA S***Associate professor, Department of Biochemistry, Kasturba Medical College,
Mangalore, Manipal University, MANIPAL, INDIA***ABSTRACT**

Prostate disorders like prostatitis, Benign prostatic hyperplasia (BPH) and prostate carcinoma are the most common disorders of the male population, the latter two being prevalent in the elderly men. PSA being the gold standard parameter to identify these diseases, is not of much importance in the differential diagnosis of prostate disorders. This study focuses on the blood levels of PSA, Urea, BUN, Creatinine BUN/creatinine ratio and eGFR and the correlations between these parameters and note the association of various disorders of prostate with renal dysfunction. Serum sample obtained from 25 patients each, diagnosed to have prostatitis, BPH and carcinoma prostate were analysed for the parameters mentioned above. Results indicated that there was a significant negative correlation of eGFR with PSA and a significant positive correlation of eGFR with BUN/creatinine ratio in patients diagnosed with BPH. No other parameters correlated in other disorders were found to be significant. Based on our results we conclude that patients with BPH are most likely to progress into kidney dysfunction and also that eGFR may be a better marker as compared to BUN/creatinine ratio in the assessment of kidney damage consequent to prostate hypertrophy.

KEY WORDS : BPH, Prostatitis, Prostate cancer, eGFR, BUN/Creatinine ratio**SUDHA K***Associate professor, Department of Biochemistry, Kasturba Medical College,
Mangalore, Manipal University, MANIPAL, INDIA*

INTRODUCTION

The most commonly diagnosed diseases of the prostate include prostatitis, prostatic cancer and benign prostatic hypertrophy. Prostate gland doubles in size during puberty and grows thereafter at around the age of 25. Prostatitis which is classified as acute and chronic is an inflammatory condition caused due to bacterial infection which may even spread to the urinary bladder. Prostatic cancer which is the second leading cause of death in elderly men, is a consequence of hypermethylation of GSTP1 gene promoter¹. Non malignant enlargement of the gland with age is referred to as benign prostatic hypertrophy (BPH). Obstruction of urethra is a common symptom in this condition. After the age of 60, 50% of the male population are likely to develop symptoms of BPH². Conventionally used laboratory markers for the diagnosis of prostate disorders are acid phosphatase and PSA, a glycoprotein produced in the benign and malignant prostate cells. However the latter has replaced the former with regard to sensitivity and specificity. It was earlier reported that serum creatinine is associated with a high risk of prostate cancer, more so in advanced cases where the chances of survival were low³. Some of the biochemical parameters that were reported to be useful in the diagnosis of prostate cancer include free PSA to total PSA ratio^{4,5} and serum to urinary PSA ratio⁶. It is evident in the current scenario, that there is a dearth of biochemical parameters for differential diagnosis of prostate disorders, paving way for the identification of newer ones. Since prostate disorders have an association with end stage renal disorders (ESRD) and is also age related⁷, this study focusses on the utility of blood levels of urea, creatinine, BUN, BUN/Creatinine ratio (BCR) and eGFR as a possible aid in the diagnosis of prostate disorders and association of these disorders with renal dysfunction.

METHODOLOGY

Inclusion Criteria

75 Patients with high PSA levels (above 4ng/ml), aged between 40-79 years, whose diseases were confirmed by biopsy report. The cases were further grouped as follows: Prostatitis (n=25), Benign prostatic hyperplasia (n=25) and Prostatic carcinoma (n=25).

Exclusion Criteria

Patients with acute urinary tract infection, smokers, alcoholics, diabetics and kidney disorders. The study was approved by institutional ethics committee and informed consent was taken from all the subjects. 5 ml venous blood was collected in a vacutainer and serum used for analysis. PSA was estimated by the method of ECLIA using COBAS e411⁸. Blood Urea was estimated by Urease/ GLDH Method⁹. Serum Creatinine was estimated by Jaffe's Method¹⁰. Estimation of eGFR was based on the following formula¹¹ Equation from the Modification of Diet in Renal Disease study (MDRD formula)

Estimated GFR (mL/min per 1.73 m²) = 1.86 x (P_{Cr})^{-1.154} x (age)^{-0.203}

Statistical Analysis was done using Kruskal Wallis test and Spearman's rank correlation, Post Hoc comparison was done using Tukey HSD test

RESULTS

There was significant change [p<0.01] in the PSA value between 3 groups-Prostate Cancer, BPH & Prostatitis (Table 1). The mean score for PSA value of Prostate Cancer (86.85±83.09) was significantly [p=0.002] higher compared to BPH (11.49±12.31) as well as Prostatitis (14.24±7.78; p=0.010]. There was no significant difference in the PSA values between BPH and Prostatitis group. Further, there were no significant changes in the mean blood values of urea, creatinine, BUN/Creatinine ratio or eGFR between the different diseases of prostate. But highest mean values for blood levels of urea, creatinine, BUN and BUN/creatinine ratio was observed in patients with prostatitis.

While eGFR was observed to be least in benign prostatic hypertrophy (Table 1). PSA was found to be significantly elevated in patients with prostate cancer in the age group 60-79yrs, while it was markedly elevated in patients with BPH in the age group 70-79yrs. The onset of BPH takes place at an earlier age as compared to prostate cancer (Table 2). No significant correlations were observed between PSA and BUN/creatinine ratio or PSA and eGFR in cancer and prostatitis.

However there was a positive correlation between BUN/creatinine ratio and PSA which was not significant in prostate disorders (Table 3). PSA and eGFR negatively correlated ($r = -0.360$) in patients with BPH and it was significant at $p < 0.05$. eGFR and BUN/creatinine was positively correlated ($r = 0.416$) in patients with BPH and it was significant at $p < 0.05$. not significant in cases (Table 4).

Table 1
Biochemical parameters in various prostate disorders: Values are Mean \pm SD

	Prostate cancer	BPH	Prostatitis
PSA(ng/ml)	86.8542 \pm 83.0948*	9.6743 \pm 6.5663	14.2481 \pm 7.7803
UREA(mg/dl)	69.5857 \pm 47.9611	74.271 \pm 68.7777	96.9454 \pm 58.8406
BUN(mg/dl)	32.5166 \pm 22.4117	34.7061 \pm 32.1391	45.3016 \pm 27.495
Creatinine (mg/dl)	1.8196 \pm 1.5827	2.7477 \pm 2.53	3.9267 \pm 1.044
BUN:Creatinine	20.7802 \pm 8.7615	16.3279 \pm 11.9684	23.0508 \pm 16.5218
eGFR(ml/min)	61.6285 \pm 36.9047	45.9545 \pm 28.9602	46.5818 \pm 34.7199

*Values are significant between the three groups ($p < 0.01$)

Table 2
PSA (ng/ml) levels in prostate disorders based on age groups: Values are Mean \pm SD

Age (yrs)	Prostate cancer	BPH	Prostatitis
<50	nil (n = 0)	Nil (n = 0)	12.25 \pm 1.56 (n=15)
50-59	Nil (n = 0)	8.173 \pm 2.58 (n=7)	26.19 \pm 8.06 (n=5)
60-69	94.68 \pm 106.63 (n=12)	7.86 \pm 2.88 (n=9)	12.54 \pm 7.46 (n=4)
70-79	98.75 \pm 85.37 (n=13)	16.74 \pm 18.5 (n=9)	7.55 (n=1)

n=number of patients

Table 3
Correlation of PSA with other parameters in prostate disorders

	"r"	p value
PSA v/s BUN:Creatinine Ratio	0.142	0.314
PSA v/s eGFR	-0.204	0.147
BUN:Creatinine Ratio v/s eGFR	0.416	0.002*
PSA v/s Age	0.265	0.050*

* Statistically significant

Table 4
Correlation between PSA and other parameters-Spearmanns Correlation based on Diagnosis

	Prostate cancer		BPH		Prostatitis	
	R	p	r	p	r	P
PSA vs eGFR	-0.524	0.183	-0.360	0.040*	0.400	0.223
PSA vs BUN/Creatinine ratio	0.120	0.778	0.005	0.979	0.173	0.611
eGFR vs BUN/creatinine ratio	0.563	0.146	0.416	0.016*	0.369	0.264

*Statistically significant

DISCUSSION

All patients enrolled in our study, showed a significant increase in PSA values with age irrespective of the type of prostate disorder, which is in agreement with earlier reports¹² PSA values are the highest in Ca prostate. Partin et al and Oesterling et al have shown that, serum PSA concentrations increase with increasing burden of malignancy in all untreated patients¹³ Benign prostatic hyperplasia which is a non malignant condition, is mostly prevalent in older men and is reported to be a major cause of lower urinary tract symptoms (LUTS)¹⁴. The doubling time of this non malignant tumor increases with age¹⁵. A tumor density of more than 0.15 as determined by serial testing of PSA for 2 years, distinguishes BPH from prostatic carcinoma¹³. Acute urinary retention is high in moderate prostate enlargement which can be predicted from the baseline serum PSA levels. It has also been reported that there is a strong correlation between prostate volume and PSA levels and therefore acute urinary retention¹⁶. However blood urea and creatinine, the markers of acute urinary retention, reported in cases with prostatic carcinoma in our study, which had significantly higher PSA values as compared to other disorders of prostate, did not correlate. This finding is in conformity with the opinion of Weinstein et al who have stated an association with chronic kidney disease and urinary bladder outlet obstruction which did not complement with prostatic enlargement¹⁷. Further, our study indicates that blood levels of

urea, creatinine, BUN were highest in prostatitis suggesting maximal renal involvement in this condition, yet eGFR was not proportionately decreased. These findings are conflicting considering the reports of Sampath Kumar et al¹⁸. However our results suggest a negative correlation between PSA and eGFR in BPH. Since PSA levels in the blood is an index of tumor size and volume⁶ and eGFR is a marker of kidney function, a negative correlation between the two parameters indicates a marked association of symptoms of renal dysfunction in BPH, which is not observed in cancer of prostate or prostatitis. In support to this observation, it has been stated earlier that many patients with kidney disease responded to surgical treatment of BPH¹⁹. A positive correlation between eGFR and BUN/Creatinine ratio in BPH is suggestive of the progression of BPH to kidney dysfunction. Similar correlations are not observed in either prostatitis or prostatic carcinoma. It has also been reported in earlier studies, that BPH can progress into prostatic cancer²⁰. On the basis of our findings, we conclude that patients with BPH, the most common type of prostatic disorder in old age, are more prone to develop renal dysfunction as compared to prostatitis or prostatic carcinoma. eGFR is a relatively better marker in this regard, although BUN /Creatinine ratio does not seem to be of much significance either in the differential diagnosis of prostatic disorders or in suggesting the type of prostate disorder that may lead to kidney dysfunction in future.

REFERENCES

1. Cairns P, Esteller M, Herman JG, Schoenberg M. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. *Clin Cancer Res*, 7(9):2727-30, (2001).
2. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of BPH. *Jr Urology*, 145(2):405-409, (1991).
3. Weinstein SJ, Mackrain K, Virtamo J, Albanes D, et al. Serum creatinine and prostate cancer risk in a prospective study. *Cancer Epidemiol Biomarkers Prev*, 18(10):2643-9, (2009).
4. Miele ME. Percent free PSA as an additional measure in a prostate cancer screen. *Clin Lab Sci*, 14(2):102-7, (2001).
5. Jacobson DJ, Robert RO. The association between Benign Prostatic hyperplasia and chronic kidney disease in community dwelling men. *Kidney Int*, 67(6):2376-82, (2005).

6. Irani J, Millet C, Levillian P, Dore B, Begon F, Aubert J. Serum to urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when prostate specific antigen level is 4-10 ng/ml. *J Urol*, 157(1):185-8,(1997).
7. Wada Y, Nakanishi J, Takahashi W, Kai N, Nakayama Y, Yamashita Y, Honda J, Ueda S. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study. *BJU Int*, 98(4):794-7,(2006).
8. Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate specific antigen : bias and molarity of commercial assays for PSA in use in England. *Ann Clin Biochem*, 43:35-48,(2006).
9. Burtis CA, Ashwood ER (editors). Renal function and nitrogen metabolites. In: Teitz textbook of clinical chemistry. 3rd edition .Philadelphia:WB Saunders Company; p1838. (1999)
10. Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood ER (editors). In: Teitz textbook of clinical chemistry. 3rd edition .Philadelphia:WB Saunders Company; p1204. (1999).
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*, 150(9):604-12,(2009).
12. Claus G Roehrborn, Raymond C Rosen. Medical therapy options for aging men with BPH: focus on alfuzosin 10 mg once daily. *Clin Interventions in Aging*, 3(3): 511–524,(2008).
13. Thomas j. Polascik, Joseph e. Oesterlingan, W Partin. Prostate specific antigen: a decade of discovery-what we have learned and where we are going? *J of Urology*, 162(2):293-306,(1999).
14. Yeon Won Park, Seung Ki Min, Jun Ho Lee. Relationship between lower urinary tract symptoms/benign prostatic hyperplasia and metabolic syndrome in Korean men. *World J Mens Health*, 30(3):183-188,(2012).
15. Berry SS, Coffey DS, Walsh PC, Euring LL. The development of human benign prostatic hyperplasia with age. *J. urol*, 132(3): 474-9,(1984).
16. Herbert Lepor. Pathology, Epidemiology and Natural History of Benign Prostatic Hyperplasia. *Rev Urol*, 9:S3-S10,(2004).
17. Rule AD, Jacques Irani, Laurent Salomon, Michel Soulié, Alexandre Zlotta, Alexandre de la Taille, Bertrand Doré, Christine Millet. Urinary/serum PSA: comparison with free /total PSA ratio in improving prostate cancer detection. *Urology*, 65(3):533-537,(2005).
18. Bhagya Lakshmi A, Sampath Kumar V, Rama Devi, Rama Rao J, Harini. Comparative study of biochemical markers in prostatitis, benign prostate hypertrophy and carcinoma of prostate with and without metastasis. *International J Pharma Biosciences*, 2(2):117-122,(2012).
19. Andrew DR, Debra JJ, Rosebud OR, Cynthia JG, Michaela EM, Steven JC. The association between benign prostatic hyperplasia and chronic kidney disease in community dwelling man. *Kidney International*, 67:2376-2382,(2005).
20. Hung SC, Lai SW, Tsai PY, Chen PC, Wu HC, Lin WH, Sung FC. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk. *Br J cancer*, 108(9):1778-83,(2013).